Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial

BACKGROUND: The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT(572) CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Gridelli, Cesare, Ciuleanu, Tudor, Domine, Manuel, Szczesna, Aleksandra, Bover, Isabel, Cobo, Manuel, Kentepozidis, Nikolaos, Zarogoulidis, Konstantinos, Kalofonos, Charalabos, Kazarnowisz, Andrzej, Korozan, Magdalena, de las Penas, Ramon, Majem, Margarita, Chella, Antonio, Griesinger, Frank, Bournakis, Evangelos, Sadjadian, Parvis, Kotsakis, Athanasios, Chinet, Thierry, Syrigos, Kostantinos N., Correale, Pierpaolo, Gallou, Catherine, Jamet, Jeanne- Menez, Vetsika, Eleni- Kyriaki, Kosmatopoulos, Kostas, Georgoulias, Vassilis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217860/
https://www.ncbi.nlm.nih.gov/pubmed/32210365
http://dx.doi.org/10.1038/s41416-020-0785-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217860/
https://www.ncbi.nlm.nih.gov/pubmed/32210365
http://dx.doi.org/10.1038/s41416-020-0785-y

Ejemplares similares